News | June 04, 2007

UltraRAD Combines Radiology Workflow, Reporting with UltraPACS

June 5, 2007 - UltraRAD Corp. announced that is has signed an agreement with StructuRad LLC to integrate StructuRad’s workflow management and advanced reporting capabilities into its industry leading UltraPACS application to offer a complete viewing and reporting solution.
UltraRAD will bundle StructuRad’s StudyManager and ReportNow applications with its PACS and integrate StructuRad’s web-based PACS. The new offering became available in June 2007.

Related Content

177Lutetium-labeled radiohybrid Prostate-Specific Membrane Antigen (177Lu-rhPSMA-10.1) is in development as a highly optimized, next generation therapeutic radiopharmaceutical
News | Radiopharmaceuticals and Tracers
Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer

April 10, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time April 10, 2024
arrow
Ga-68 has a very short half-life, which presents logistical challenges in distribution
News | Radiopharmaceuticals and Tracers
RLS Radiopharmacies Partners with Eckert and Ziegler to Expand Production of Gallium-68-Based Radiopharmaceuticals

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
During the blood pool phase, it significantly shortens the T1 and T2 relaxation times of the blood, thus achieving bright blood effects in T1-weighted imaging and dark blood effects in T2/T2*-weighted imaging. In the delay phase, by the local aggregation of ferumoxytol disrupting the uniformity of the local magnetic field, the decrease of the transverse magnetization vector Mxy is expedited, resulting in a negative contrast effect.
News | Molecular Imaging
Exploring Ferumoxytol: A Frontier in MRI Contrast Agents

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
First reported clinical results from independent clinical experience by University of Augsburg demonstrated encouraging preliminary data for 177Lu-rhPSMA-10.1
News | Radiopharmaceuticals and Tracers
Blue Earth Therapeutics Announces Publication of Results from Independent Clinical Experience with 177Lu-rhPSMA-10.1 in Treatment of Metastatic Castrate Resistant Prostate Cancer

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
arrow
Agreement demonstrates PanTera’s unique ability to support the radionuclide therapeutics industry in bringing new cancer treatments to patients
News | Radiopharmaceuticals and Tracers
PanTera signs agreement with Bayer for the supply of actinium-225

February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of ...

Time February 14, 2024
arrow
Radformation, a global pioneer in radiation oncology software solutions, is pleased to announce its strategic partnership with Icon Group, a worldwide leader in comprehensive cancer care.
News | Quality Assurance (QA)
IBA Acquires Radcal Corporation to Expand Medical Imaging Quality Assurance Offering and Strengthen US Presence

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
(A) PET images of [68Ga]Ga-DOTA-ZCAM241 uptake at baseline and 3, 7, and 12 days after injection as inflammatory arthritis developed in single representative individual mouse. Images are normalized to SUV of 0.5 for direct comparison between time points. (B) CD69 immunofluorescence Sytox (Thermo Fisher Scientific) staining of joints of representative animals during matching time points.
News | PET Imaging
New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear

February 9, 2024 — A novel PET imaging technique can noninvasively detect active inflammation in the body before ...

Time February 09, 2024
arrow
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Mid-Winter Conference drew global experts exchanging the latest innovations in diagnostic and molecular imaging, cancer therapies, clinical trials and theranostics, as well and the role of artificial intelligence (AI) in nuclear medicine during its Feb. 1-3, 2024 meeting in Orlando, FL.
News | SNMMI
Society of Nuclear Medicine and Molecular Imaging (SNMMI) Mid-Winter Conference Focuses on Theranostics, AI, Diagnostic Imaging Innovations and Clinical Trials

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
The growing emphasis on personalized treatment plans based on a patient’s unique genetic profile and tumor characteristics aims to optimize treatment outcomes while minimizing side effects, and this technology is being used in pediatric oncology. Getty Images
Feature | Radiation Oncology | By Melinda Taschetta-Millane
Special Report: Radiation Oncology Takeaways from RSNA23

Over the past several years, technological advancements have driven the development of more precise and targeted ...

Time January 16, 2024
arrow
Under the new agreement, NorthStar will manufacture and distribute patient doses for ongoing Curadh Ac-225 clinical studies and provide Ac-225 for commercial use upon NorthStar’s submission of a Type II Drug Master File (DMF) to the FDA
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes and Curadh MTR Enter Strategic Collaboration Agreement for Development and Production of Actinium-225 (Ac-225)-based Therapeutic Radiopharmaceuticals for Treatment of Primary and Metastatic Solid Tumors

January 5, 2024 — NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and ...

Time January 05, 2024
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now